secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRATED BIOPHARMA INC (INBP)
CIK:        0001016504
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001437749-23-031188
Event type: earnings
Sentiment:  neutral
Materiality: 0.30
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integrated BioPharma Q1 revenue up 4.9% to $12.9M; net loss widens to $59K
--------------------------------------------------------------------------

- Revenue $12.9M vs $12.3M YoY, a 4.9% increase.
- Operating loss of $54K vs operating income of $30K in prior year.
- Net loss of $59K ($0.00 per share) vs net loss of $35K ($0.00 per share).
- Two largest customers represent 91% of Q1 revenue in Contract Manufacturing Segment.
- Co-CEOs cite revenue growth from top customers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1016504/000143774923031188/0001437749-23-031188-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1016504/000143774923031188/inbp20231107_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-031188

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer